Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy

Case series (n=90) found elevated plasma glucose at admission, treatment with insulin and β-blockers were associated with increased mortality, whereas the use of dipeptidyl peptidase 4 inhibitors was associated with a lower risk of mortality (HR 0.13, 95% CI 0.02–0.92).

Diabetes Care